A randomised double-blind trial of the effects of hormone therapy on delayed verbal recall in older women

Sunnybrook and Women's College Health Sciences Centre (Canada)0 sites146 target enrollmentSeptember 1, 2005

Overview

No summary available.

Registry

who.int

Start Date

September 1, 2005

End Date

TBD

Last Updated

11 years ago

Study Type

Interventional

Sex

All

Sponsor

Sunnybrook and Women's College Health Sciences Centre (Canada)

•1\. History of myocardial infarction, bypass surgery, angioplasty or unstable angina for more than one year
•2\. Admitted after approval from family physician
•3\. Non\-demented memo\-impaired women who are at a greater than or equal to 50% probability of developing AD

•1\. Diagnosis of a dementing disorder, including AD
•2\. History of any conditions that might affect cognitive functioning, e.g., chronic alcohol or drug abuse, stroke, hypoxia, intracranial mass lesions, psychoses, brain trauma, or other neurological diseases
•3\. A medical condition with a probable prognosis of death less than two years or any unstable medical condition, including active hepatic dysfunction or disease
•4\. Conditions that might be exacerbated by oestrogen, including history of breast cancer, endometrial cancer, abnormal mammogram, abnormal pelvic ultrasound
•5\. Congestive heart failure (New York Heart Association \[NYHA] Class III and IV)
•6\. History of myocardial infarction, bypass surgery, angioplasty or unstable angina within the past year
•7\. Current or history of thromboembolic event
•8\. Use of donepezil, galantamine, rivastigmine or hydergine less than two weeks before initiation of oestrogen therapy
•9\. Past use of any mode or dose of hormone replacement therapy for duration longer than half the period of time that it was used
•10\. 0\.50 probability of developing AD in two years based on performance on the API